Fig. 1.

Flow cytometric analysis of cancer stem cell (CSC) content using CD133 as a representative marker of brain tumor CSCs. (A) Direct analysis of CD133+ content in patient-derived orthotopic xenograft (PDOX) tumors. (B) Comparison of CD133+ cell content between neurospheres and fetal bovine serum-based monolayer cultures in 3 glioblastoma models. Isotype control was used for each sample to set baseline. (C) Direct analysis of CD44+ and/or CD49f+ cells through double staining in 5 PDOX models.